Abstract. The present study aimed to develop a monoclonal antibody (mAb)-based double functional probe for PET and near-infrared fluorescence (NIRF) targeting CD20 and to cross validate the targeting efficacy of this dual functional probe. NuB2, anti CD20 mAb was conjugated with Alexa Fluor 750 and 64 Cu through DOTA chelator. PET and NIRF imaging was carried out at 30 min and 24 h post-injection with 64 Cu-DOTA-NuB2-Alexa Fluor 750 in CD20 positive Raji lymphoma-bearing mice. Fluorescence intensity and radio-activity were studied by ex vivo biodistribution study at 30 min, 24 and 48 h after injection. Raji tumor showed significantly higher uptake of DOTA-NuB2-Alexa Fluor 750 than that of DOTA-Alexa Fluor 750 (p<0.05). Significant correlation was obtained between the organ-to-muscle ratios measured by the radioactivity and fluorescence intensity (p<2.2e-16, r=0.94). Our findings demonstrate the effectiveness and feasibility of preparing an effective mAbbased dual functional imaging agent for PET and NIRF targeting the CD20 expression in lymphoma.
Introduction
Near infrared fluorescence (NIRF) imaging is promising in the field of optical imaging as it offers unique advantage for diagnostic imaging of solid tumors with high sensitivity (1) . NIR light with wavelength of 700-900 nm causes minimal autofluorescence and is minimally absorbed by hemoglobin as well as by water and lipids (2, 3) . On the other hand, positron emission tomography (PET) is an established, highly sensitive and a quantitative tomographic imaging modality (4) . However, radiotracers have the limitation of low photon counts thus requiring longer scan times as well as they have definite halflives and the radiation dosage which prevents the longitudinal imaging in patients. Although NIRF and radiotracers possess excellent photophysical properties, none are tumor specific. Radiolabeled or fluorescence labeled antibodies/peptides have been vigorously investigated to overcome these problems. By combining optical imaging for enhanced photon signal count without agent half-life concerns and PET imaging with high sensitivity at deep tissue detection, mAb based dual-labeled imaging agent allows cross validation and direct comparison between nuclear and optical imaging and allows a comprehensive picture of the imaging agent distribution and provides a rapid and efficient imaging method for basic research and clinical diagnosis (4) (5) (6) (7) .
Few studies on dual-labeled probe for imaging has been reported so far. Protein or peptide was dual-labeled as an imaging agent for PET and NIRF (8, 9) . Another study reported dual labeled monoclonal antibody (mAb)-based imaging agent for SPECT and NIRF (10) . 64 Cu-labeled peptides have also shown promise for PET and targeted radiotherapy in tumor-bearing animals and for diagnostic imaging of patients (4, 11) . Although radiolabeled peptides accumulate within few hours in tumor unlike mAb, the absolute tumor uptake is generally considerably less than that with labeled mAb. Radiolabeled mAb display more rapid pharmacokinetics and impressive outcome. Excellent promising results have been obtained with radiolabeled anti-CD20 mAb in the treatment of non-Hodgkin's lymphoma (12) .
To the best of our knowledge no study has been reported so far in dual labeled mAb-based imaging agent for PET and NIRF. The aim of the present study is to develop a monomolecular multimodal imaging agent for PET and NIRF targeting CD20 positive lymphoma that will have better targeting ability, good pharmacokinetics and better imaging and would be able to cross validate the findings of PET and NIRF modalities.
Materials and methods
Cell lines. Human lymphoma cell lines Raji was purchased from American Type Culture (ATCC, Rockville, USA) and 
Radiolabeling.
64 Cu was synthesized by in-house cyclotron (kindly provided by Japan Atomic Energy Association, Takasaki, Japan). DOTA-NuB2 conjugated with Alexa Fluor 750 was labeled with 64 CuCl 2 . To the solution of acetic buffer (3 M, pH 6.0), 50 μg of DOTA-NuB2-Alexa Fluor 750 was added and was radiolabeled with 64 CuCl 2 and the mixture was incubated at 40˚C for 1.5 h. 64 Cu-DOTA-NuB2-Alexa Fluor 750 was purified by Bio-Spin 6 Tris column using phosphate buffer as the mobile phase. The radiochemical purity was determined by thin-layered chromatography.
Biodistribution study in tumor-bearing mice. Animal experiments were conducted in accordance with our institutional guideline and were approved by the Gunma University Animal Care Committee. Balb/c nude mice, 6 weeks old, female were purchased from CLEA (Tokyo, Japan) and were maintained under specific pathogen-free conditions and were provided with sterile food and water. Nude mice were inoculated subcutaneously with CD20 expressing Raji cells. When the tumors were ~7-8 mm in diameter, the animals were injected intravenously with 64 Cu-DOTA-NuB2-Alexa Fluor 750 (10 MBq/mouse). Group of 4 mice were used for the experiments. At 24 and 48 h after injection, mice were sacrificed by decapitation and aliquots of blood were collected. Organs of interest were excised and weighed, and the radioactivity counts was measured with a well counter (ARC-7001, Aloka, Tokyo, Japan). The data are expressed as % injected dose/gram (ID/g). The system consists of an optical head that includes a liquid crystal tunable filter with a bandwidth of 20 nm and a scanning wavelength range of 500-950 nm with a custom designed, spectrally optimized lens system that relays the image to a scientific-grade megapixel CCD. The tunable filter was automatically stepped in 10 nm increments from 650 to 850 nm while the camera captured images at each wavelength with constant 1 sec exposure (total acquisition time was ~25-30 sec). The resulting 21 TIFF images (spectral cube, containing a spectrum at every pixel) were loaded into vendor software (Nuance 1.4.0) and analyzed. Spectral unmixing using a normal mouse as the autofluorescence signal yielded the pseudo color images of the pure mice autofluorescence and the Alexa Fluor 750. The animals were anesthetized with Nembutal before the acquisition was started.
Small animal PET scan and image analysis. PET imaging of
For ex vivo studies, the excised tissues were subjected to fluorescence imaging. The fluorescence intensity of each tissue was measured and normalized to photons per second with an ROI covering the entire tissue. The total fluorescence flux of each tissue was divided by its weight. The data were calculated as %ID/g. Statistical analysis. All statistical analysis was performed with Stat View 5.0. Spearman's correlation was performed between organ-to-muscle ratios of PET and NIRF. The Kruskal Wallis test was performed to calculate the difference between the variables.
Results

Synthesis of
64 Cu-DOTA-NuB2-Alexa Fluor 750. The radiochemical purity of 64 Cu-DOTA-NuB2-Alexa Fluor 750 was 80%. The number of DOTA chelators bound to a single molecule of NuB2 was found to be ~10. The absorption and fluorescence emission spectra of 64 Cu-DOTA-NuB2-Alexa Fluor 750 and DOTA-NuB2-Alexa Fluor 750 were similar to Alexa Fluor 750 suggesting that the fluorescence properties of the Alexa Fluor 750 were not altered on conjugation with the antibody. The number of Alexa Fluor 750 conjugated to the DOTA-NuB2 was determined by spectrophotometer and the mole of dye to antibody ratio was ~2.
In vivo small animal PET and optical imaging. (Fig. 1a and b) . Similarly, no uptake of 64 Cu-DOTA-NuB2-Alexa Fluor 750 is seen in the tumor at 30 min with PET and NIRF ( Fig. 1 c and e ) whereas significant uptake of 64 Cu-DOTA-NuB2-Alexa Fluor 750 is seen at the tumor region after 24h post-injection as determined by the NIRF and PET imaging (Fig. 1d and f, respectively) . Liver showed prominent uptake of the probe on PET imaging at 24 h (Fig. 1d) .
Ex vivo nuclear and optical imaging. Ex vivo study was performed on harvested tissues and the biodistribution experiment showed the uptake of 64 Cu-DOTA-NuB2-Alexa Fluor 750 in tumor and other organs as determined by radioactivity and fluorescence intensity ( Fig. 2A and B, respectively). The radioactivity in the liver activity reached a plateau at 24 h (30.28±0.76) point owing to non-specific uptake of the probe by the reticuloendothelial system (RES) but dropped gradually over time (48 h, 24.88±1.10). The activity of liver measured by the fluorescence was high at 24 h (9.62±5.67), and dropped steadily at 48 h (2.50±0.51). The absolute signal intensity from NIRF is quite different than that of PET signal. This is likely due to the decomposition of DOTA complex and trapping of 64 Cu inside the tumor or degradation of the fluorophore thus decreasing the fluorescence intensity. The uptake measured by the radioactivity vs. fluorescence intensity in other organs such as muscle was very low at 24 h (3.41±1.20 vs. 1.41±1.60) and 48 h (1.63±0.33 vs. 0.00). The uptake of the probe in tumor increased with time, it was 3.19±0.58 vs. 0.25±0.30 at 30 min, 13.09±2.01 vs. 13.73±7.00 at 24 h and reached a peak at 48 h post-injection (16.34±2.75 vs. 17.92±8.12). Significantly higher radioactivity or fluorescence intensity was observed in tumor than that of muscle at any time point (p<0.001). When the mice were injected with DOTA-Alexa Fluor 750, the uptake in the tumor was significantly lower (p<0.05, data not shown) than that of DOTA-NuB2-Alexa Fluor 750 as shown in the Fig. 3 .
Strong correlation was obtained between the organs-tomuscle ratios of liver, kidney, intestine, spleen, pancreas, lung, heart, bone and tumor measured by two different modalities (p<2.2e-16, r=0.94) as shown in the Fig. 4 . A significant correlation was obtained between the radioactivity and fluorescence intensity in all organs at each time point evaluated (data not shown). 
Discussion
The development of mAb-based imaging agent that can produce detectable signal in multimodal imaging system such as PET and optical imaging would facilitate the clinical application of optical molecular probes, while limiting the toxicity of the probe. The present study demonstrated that 64 Cu-DOTA-NuB2-Alexa Fluor 750 exhibits strong and specific binding to the tumor expressing CD20 antigen as confirmed by the ex vivo biodistribution study and in vivo PET and NIRF imaging. The tumor uptake was typically high with lower RES uptake and showed better pharmacokinetics when compared with the previous dual-labeled studies with peptides. Development of a mAb-based dual functional imaging agent containing both NIRF and radionuclides for PET could facilitate the translation of NIRF imaging into clinical applications to provide synergistic advantages over single imaging modality (13) . A strong correlation between NIRF and PET imaging can be assured, as both NIRF and PET are tomographic modalities (14) . Thus, the development of a dual-labeled probe offers a convenient and direct approach for accurately assessing the pharmacologic properties of NIRF in preclinical studies (15) . Previously quantum dots (QD) based dual function probe for imaging of tumor with PET and NIRF has been reported (8, 9) . However, the present large-sized QDs are ineffective for in vivo targeting of the tumor receptor and have rapid uptake in the RES and slow renal clearance (14) . The synthesis of small-sized QDs that are highly stable and biologically effective is critical. The toxicity of cadmium present in QD and the huge molecular structure of the QD resulting in the high RES uptake and low target uptake cannot be ignored when considering application in the clinical practice.
The present study demonstrated significantly higher uptake in the tumor than that in the muscle region at 24 and 48 h post-injection with 64 Cu-DOTA-NuB2-Alexa Fluor 750. When mice were imaged with DOTA-Alexa Fluor 750, the uptake in tumor was significantly lower at 30 min, 24 h and 48 h compared with DOTA-NuB2-Alexa Fluor 750, which excluded the possibility of non-specific binding of the antigen to the free DOTA-Alexa Fluor 750. The liver signal intensity as demonstrated by PET and NIRF was higher than that of tumor or muscle. The presence of Fc receptor in the liver might have lead to the non-specific binding of intact mAb in which the Fc portion is not removed (15) . However, the signal intensity decreased after forming a plateau at 24 h, which allowed sufficient time for the probe to reach the target. It confirmed that the probe could extravasate to reach the receptor targets expressed on the surface of the tumor cells, thus, enhancing the specific targeting and enabling the escape from the RES (14) . The extravasation study should be verified in our future studies with intravital microscopy. The clearance of 64 Cu-DOTA-NuB2-Alexa Fluor 750 is usually through the hepatic pathway like any other mAb-based imaging agent. Even though the in vivo studies showed better results the 64 Cu-DOTA-NuB2-Alexa Fluor 750 is a stable compound, 64 Cu-DOTA-mAb is reported to dissociate from the chelator and the free 64 Cu accumulates in the liver where it is incorporated into endogenous copper binding proteins such as ceruloplasmin and superoxide dismutase (14, 16) which shows higher uptake in the liver by PET and might cause the discrepancy between PET and NIRF. Alternatively, one could use more stable chelating agents with 64 Cu to obtain better pharmacokinetics. This approach is currently under investigation in our laboratories. The present study is based on the assumption that the organ activity of PET shows true measurement of well counting and this has been validated in previous studies (17) and the distribution of 64 Cu is a true reflection of the localization of NIRF imaging agent in various organs as supported by previous studies (8, 9, 14) .
In conclusion, we successfully developed a mAb-based dual functional probe, 64 Cu-DOTA-NuB2-Alexa Fluor 750 which can be characterized for in vivo imaging of the CD20 expression for early and sensitive lesion detection, patient selection for better treatment monitoring and dose optimization. A statistically significant correlation was observed between radioactivity and fluorescence intensity, confirming the stability of the dual functional probe, thus raising the probability facilitating the integration of optical imaging into existing PET system thereby accelerating the use of the combined strength of both modalities. 
